Article citationsMore>>

Jellinger, P.S., Handelsman, Y., Bell, D.S., Bloomgarden, Z.T., Brinton, E.A., Davidson, M., Fazio, S., Fonseca, V.A., Garber, A.J. and Grunberger, G. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice, 23, 479-497.
https://doi.org/10.4158/EP171764.GL

has been cited by the following article:

• TITLE: Familial Hypercholesterolemia with Two Mutations in LDLR Gene: A Case Report and Literature Review

  AUTHORS: Hui Zhou, Xiaoxiao Song, Bo Sun, Linjin Wu, Thachapol Napawan, Wei Gu

  KEYWORDS: Familial Hypercholesterolemia, Inherited Disease, Metabolism, Low-Density Lipoprotein Receptor, Gene Mutation

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.8 No.10, October 23, 2017

  ABSTRACT: We report a case of Familial hypercholesterolemia (FH) with two mutations in low density lipoprotein receptor (LDLR) gene and speculate the correlation between the newly discovered mutation type of LDLR gene and FH. We collected and analyzed the clinical data of the proband in the case and her immediate family members, and detected the LDLR, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) and Apolipoprotein B (Apo B) gene in the peripheral blood of all the participants. We found that the curative effect of the patient is limited, but no obvious complication was detected. Genetic testing results pointed out that there were two mutations in the patient’s LDLR gene. One was p.W483* mutation in exon 10 (c. 1448 G > A), another was p.T534I mutation in exon 11 (c. 1601 C > T). The p. W483* mutation in exon 10 was detected in the father and sister, additionally p. T534I mutation in exon 11 was detected in the mother. Both the two LDLR gene mutations are inherited from her parents. We hypothesize that the patient in this case was a complex heterozygote. The newly discovered mutation gene (T534I) may be one of the important causes of dyslipidemia in patients, and its adverse effects are more serious than W483* which have been reported. Also, we predict that the T534I mutation will not cause serious early onset of cardiovascular complications.